PIPELINE

Pre-clinical

Phase I

Phase II

Phase III

NDA


CUTX-101 (Copper Histidinate) for Menkes Disease

Phase 3 Study Ongoing
70%

AAV-ATP7A Gene Therapy for Menkes Disease

Preclinical
17%


= Orphan Drug Designation
= Fast Track Designation